Product Information
NICOTINE 2 MG MINI LOZENGE is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.3742 per EA under NDC 45802008902. Its NADAC has been published 529 times since Aug 17, 2016.
FDA first approved this application on Oct 9, 2012.
Strength
2 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802008902
Classification
Generic
Dosage Form
LOZENGE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NICOTINEApproval Type
Generic (ANDA)
FDA Application
ANDA203690FDA Approved
10/9/2012
On Market Since
7/8/2016
Pharmacological Classes
Price Statistics
The NADAC for NICOTINE 2 MG MINI LOZENGE has been published 529 times since Aug 17, 2016, and over the history we have for it it has risen 7.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3742 per EA |
|---|---|
| All-time high | $0.4147 (Aug 10, 2022) |
| All-time low | $0.3022 (Jul 17, 2024) |
| 52-week high | $0.3742 |
| 52-week low | $0.3432 |
| Median price | $0.3625 |
| Average price | $0.3645 |
| Largest weekly change | -18.8% (Apr 17, 2024) |
| Weeks tracked | 529 |
| Tracking since | Aug 17, 2016 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nicotine Polacrilex market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Nicotinic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NICOTINE 2 MG MINI LOZENGE?
The current National Average Drug Acquisition Cost (NADAC) for NICOTINE 2 MG MINI LOZENGE, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.3742 per EA (NDC 45802008902), effective Sep 30, 2026.
How has the price of NICOTINE 2 MG MINI LOZENGE changed over time?
Over the history we have for it, the NADAC for NICOTINE 2 MG MINI LOZENGE has risen 7.5%. It has been tracked across 529 weekly CMS publications since Aug 17, 2016.
What are the highest and lowest recorded NADAC prices for NICOTINE 2 MG MINI LOZENGE?
Since Aug 17, 2016, the NADAC for NICOTINE 2 MG MINI LOZENGE has ranged from a low of $0.3022 (Jul 17, 2024) to a high of $0.4147 (Aug 10, 2022), with a median of $0.3625 per EA.
Are there cheaper alternatives to NICOTINE 2 MG MINI LOZENGE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NICOTINE 2 MG LOZENGE, is $0.3468 per EA — about 7% below NICOTINE 2 MG MINI LOZENGE.
Who manufactures NICOTINE 2 MG MINI LOZENGE?
NICOTINE 2 MG MINI LOZENGE (NDC 45802008902) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.